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catecholamine family. The PNMT structure reported
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University of Queensland
Brisbane, QLD 4072 Adrenaline (epinephrine) accounts for 5%–10% of the
total catecholamines in the central nervous systemAustralia
2 Victorian College of Pharmacy (CNS), yet its function therein is not well understood [1].
Adrenaline is synthesized in vivo from noradrenaline inMonash University
Parkville, VIC 3052 a reaction catalyzed by phenylethanolamine N-methyl-
transferase (PNMT, EC 2.1.1.28), a 30-kDa enzyme thatAustralia
3 Department of Medicinal Chemistry utilizes the cofactor S-adenosyl-L-methionine (AdoMet)
to methylate the amine of noradrenaline (Figure 1). EarlyThe University of Kansas
Lawrence, Kansas 66045 studies on the distribution of PNMT-containing neurons
in the brain led to the suggestion that CNS adrenaline
is involved in the central control of blood pressure [2],
respiration [3], and pituitary hormone secretion [4]. MoreSummary
recently, it has been implicated in the effects of ethanol
intoxication [5] and the neural degeneration observedBackground: Adrenaline is localized to specific regions
in Alzheimer’s disease [6]. Concrete evidence that CNSof the central nervous system (CNS), but its role therein
adrenaline regulates or contributes to any of these pro-is unclear because of a lack of suitable pharmacologic
cesses would make the neurotransmitter a prime candi-agents. Ideally, a chemical is required that crosses the
date for drug intervention.blood-brain barrier, potently inhibits the adrenaline-syn-
The uncertainty in clarifying the role of CNS adrenalinethesizing enzyme PNMT, and does not affect other cate-
lies in the fact that there are no suitable pharmacologicalcholamine processes. Currently available PNMT inhibi-
tools available. The problem is as follows. When CNS-tors do not meet these criteria. We aim to produce
active PNMT inhibitors such as SK&F 64139 (Figure 1)potent, selective, and CNS-active PNMT inhibitors by
are administered to hypertensive rats, there is a de-structure-based design methods. The first step is the
crease in brain adrenaline content and peripheral bloodstructure determination of PNMT.
pressure [7]. By contrast, PNMT inhibitors such as SK&F
29661 (Figure 1), which do not cross the blood-brainResults: We have solved the crystal structure of human
barrier, are ineffective in lowering blood pressure [8]. AtPNMT complexed with a cofactor product and a submi-
first glance, these data support the hypothesis that CNScromolar inhibitor at a resolution of 2.4 A˚. The structure
adrenaline is involved in blood pressure control. How-reveals a highly decorated methyltransferase fold, with
ever, interpretation is complicated by the fact that mostan active site protected from solvent by an extensive
PNMT inhibitors also interact with central 2-adrenocep-cover formed from several discrete structural motifs.
tors [9]. Thus, it is not clear whether the observed de-The structure of PNMT shows that the inhibitor interacts
crease in blood pressure upon the administration ofwith the enzyme in a different mode from the (modeled)
CNS-active PNMT inhibitors is caused by a reductionsubstrate noradrenaline. Specifically, the position and
in levels of brain adrenaline due to PNMT inhibition ororientation of the amines is not equivalent.
is a result of the interaction of the inhibitors with 2-
adrenoceptors.
Conclusions: An unexpected finding is that the struc- In order to investigate the physiological role of CNS
ture of PNMT provides independent evidence of both adrenaline, we have initiated a program to develop po-
backward evolution and fold recruitment in the evolution tent and selective inhibitors of PNMT that are CNS ac-
of a complex enzyme from a simple fold. The proposed tive. Here, we report the achievement of a critical mile-
evolutionary pathway implies that adrenaline, the prod- stone in this program: the determination of the crystal
uct of PNMT catalysis, is a relative newcomer in the structure of human PNMT (hPNMT). The structure of the
enzyme incorporates two bound ligands, the inhibitor
4Correspondence: j.martin@imb.uq.edu.au SK&F 29661 (Ki for hPNMT  0.58 M; G.L.G., M.J.M.,
5Present address: Health Sciences and Technology Society, Harvard and K.R. Criscione, unpublished data) and S-adenosyl-
Medical School, 250 Longwood Avenue, Boston, Massachusetts L-homocysteine (AdoHcy), the demethylated product of
02446.
the cofactor AdoMet. The crystal structure thus identi-6Present address: College of Pharmacy, University of Michigan, Ann
Arbor, Michigan 48109.
7Present address: CSIRO Health Sciences and Nutrition, Parkville, Key words: adrenaline; epinephrine; catecholamine synthesis;
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around Pro42–Pro43, which forms part of an unusual
type VIa (cis-Pro)  turn [11]. This turn is positioned im-
mediately after the two N-terminal  helices (1 and
2) and before helix 3 in the polypeptide sequence. A
conformational change around this turn might allow the
N-terminal helices of the active site cover to be snapped
on and off during the catalytic cycle. Alternatively, the
active site may be opened through movement of a flexi-
ble loop that partially blocks one end of the active site
(shown in green in Figure 3). This loop has no defined
secondary structure and is unusual in that every second
residue (from Pro162 to Pro174) is either a proline or a
glycine. The local sequence of this polyproline region
is highly conserved among the known PNMTs (human,
bovine, rat, and mouse), but is not conserved in other
methyltransferases (MTs).
An MT Fold with a Ligand Binding Lid
Despite an overall sequence identity of 10%, the
PNMT fold is clearly related to that of other MTs that
use AdoMet for the methylation of small molecules, pro-
Figure 1. PNMT Reaction and Inhibitors teins, or nucleic acids. Functionally, PNMT belongs to
(a) PNMT uses the methyl donor S-adenosyl-L-methionine (AdoMet) the small molecule subfamily of MTs. Structures of other
to catalyze the formation of adrenaline from noradrenaline. Both
small molecule MTs include catechol O-MT (COMT) [12]noradrenaline and adrenaline are inactivated through methylation
and glycine N-MT (GNMT) [13]. It is particularly notewor-of their catechol hydroxyls by COMT, which also uses AdoMet as
thy that PNMT and COMT are both part of the catechola-a methyl donor.
(b) The chemical structure of PNMT inhibitor SK&F 64139. mine pathway and they both interact with adrenaline and
(c) The chemical structure of PNMT inhibitor SK&F 29661. noradrenaline. However, their roles are quite different.
PNMT converts noradrenaline into adrenaline by methyl-
ating the noradrenaline amine, whereas COMT inacti-
fies the critical binding sites within the enzyme active vates both catecholamines by methylating the catechol
site and shows that the amine of the bound inhibitor hydroxyls. A comparison of the two structures shows
is relatively distant from the cofactor. A model of the that PNMT is a much more embellished structure than
noradrenaline substrate in the active site shows that, COMT (Figure 3), with large insertions at five points
for methylation to occur, it must bind in an alternate in the consensus MT fold. By comparison, COMT is a
mode from that of the inhibitor. The PNMT crystal struc- streamlined structure with no inserts in the fold, except
ture will be used in the structure-based design of im- at the N terminus. Strikingly, four of the five insertions
proved inhibitors that could eventually be developed in the MT fold of PNMT provide the motifs that enclose
into therapeutic agents with novel pharmacological ac- the active site, which contribute a significant proportion
tivity. of ligand binding residues. In stark contrast, the active
site of COMT is completely solvent exposed, and all of
the ligand binding residues are provided from within theResults and Discussion
core MT fold.
COMT and PNMT are both structurally similar toOverall Fold
The crystal structure of hPNMT (Figure 2) was deter- GNMT (Table 2), an enzyme that is not part of the cate-
cholamine pathway. GNMT is a complex, functionallymined at 2.4 A˚ resolution by multiple isomorphous re-
placement (Table 1). The polypeptide fold of hPNMT diverse protein [14] that is thought to play a role in
folate binding, regulating AdoMet levels in the liver, andincorporates an / domain with a central 7-stranded
mixed  sheet (1–7) flanked on either side by helices activating transcription of metabolizing enzymes in re-
sponse to polycyclic aromatic hydrocarbons. GNMT can(3–5, B, and D–E). The binding sites for substrate
and cofactor are located on one edge of the  sheet, interconvert between dimeric and tetrameric forms and
is regulated by posttranslational modifications such asand these binding sites are enclosed by a tight cover
comprising several motifs, an N-terminal helical region phosphorylation and auto-inhibition (through interaction
of its N terminus with the active site of an adjacent(1–2), a short  helix (6), a  hairpin (H1 and H2),
and an  loop [10]. These motifs (shown in blue in Figure subunit [15]).
The MT folds of PNMT and GNMT are by far the most3) are donated from discrete parts of the polypeptide
fold and are likely to be critical for enzyme function, since similar of the three pairs of enzyme structures (Table 2).
Notably, the sequence identity of the structurally similarthey contribute around 40% of the residues that interact
with the cofactor product and inhibitor (Figure 3). regions of PNMT and GNMT, while still low at less than
20%, is much higher than for PNMT versus COMT orAccess to the enclosed active site is not obvious but
could be gained through a conformational change for GNMT versus COMT. Even more striking than the
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Figure 2. hPNMT Crystal Structure
(a) A stereo view of the backbone trace of hPNMT, with every tenth residue labeled.
(b) A backbone trace of hPNMT shown colored from blue (N terminus) to red (C terminus), with helices shown as coils and strands shown as
arrows. The orientation used is the same as that in the stereo view. Ligands bound to the enzyme are shown in light gray (AdoHcy) and dark
gray (SK&F 29661).
(c) Electron density at the active site from the refined 2.4 A˚ resolution 3Fo-2Fc map, displayed at a contour level of 1. The final refined
coordinates are shown for comparison.
superimposition statistics are the other similarities be- cally more closely related to each other than they are to
COMT in that they both catalyze N-methylation, whereastween PNMT and GNMT. First, they share exactly the
same pattern of insertions in the MT fold, an additional COMT catalyzes O-methylation.
40–50 residues at the N terminus, a helical insert be-
tween B and 3, a small helix (6) inserted between Implications for Evolution
What do these findings tell us about the evolution of4 and D, a  sheet insertion between 5 and E,
and an  loop insertion between 6 and 7 (Figure 3). these enzymes? The austerity of the MT structure of
COMT compared with the much more elaborate struc-Moreover, neither PNMT nor GNMT has extra residues
at the C terminus of the consensus MT fold; although, ture of PNMT suggests that PNMT may have evolved
from COMT through backward evolution [16]. This is athis is a common insertion point in the MT family. No
other known MT structure has this same pattern of inser- process in which an enzyme within the same pathway
that binds the same ligand is recruited and evolves totions in the MT fold. Furthermore, no other known MT
structure has an enclosed active site. Both PNMT and carry out alternate chemistry on the ligand. The TIM
barrel enzymes provide good examples of this type ofGNMT have covered active sites, and, in both cases,
the cover is unusually contributed from several discrete evolution [17]. However, in the case of PNMT, there is
a twist. COMT and PNMT do not bind their identicalinsertion motifs. However, the cover of GNMT does not
appear to be as tightly closed over the active site as substrates in the same way; their catecholamine binding
modes are different. Furthermore, they have not evolvedthat of PNMT and thus does not contribute significantly
to ligand binding. Finally, GNMT and PNMT are catalyti- substantially different chemistries; they both carry out
Structure
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Table 1. Data Collection, Phasing, and Refinement Statistics for hPNMT
Data Set Resolution (A˚) Completea (%) Rmergeb (%) I/I RmsfhEc
Native 50–2.3 90 5.1 18.9
(2.38–2.30)d (54) (27.4) (2.1)
EMPe 50–3.0 95 9.6 10.6 1.24
(3.11–3.0) (94) (31.1) (2.3)
Iodinef 50–2.7 97 9.2 11.4 0.72
(2.8–2.7) (90) (32.3) (2.3)
Refinement Number of Nonhydrogen Atoms
Resolution (A˚) 50–2.4 Protein and ligands 4,234
Rcryst (%)g 23.1 Water 126
Rfree (%)h 27.2
Reflections (work set) |F|  0 32,279
Reflections (test set) |F|  0 3,236
Rmsd from Ideality Ramachandran Plot (Nonglycine)
Bond lengths (A˚) 0.008 Most favored 90.8
Bond angles () 1.45 Disallowed 0.0
a Complete indicates the number of measured independent reflections divided by the total theoretical number of independent reflections.
b Rmerge  	|Ii 
 Ih|/	 Ii, where Ii is the ith observation of the intensity of the reflection, h, and Ih is the mean intensity for reflection h from
multiple measurements.
c Rmsfh/E is the phasing power, where fh is the heavy atom structure factor amplitude and E is the residual lack of closure error. The overall
figure of merit is 0.31.
d Numbers in parentheses refer to the highest resolution shell.
e EMP, ethylmercuryphosphate.
f Iodine, 7-iodo-1,2,3,4-tetrahydroisoquinoline.
g Rcryst  	h|Fo–Fc|/	hFo|, where Fo and Fc are the observed and calculated structure-factor amplitudes for each reflection, h, respectively.
h Rfree [38] is calculated as for Rcryst from 10% of the data excluded from refinement.
a methylating reaction and they both use the same co- two ligands, the cofactor product AdoHcy and an inhibi-
tor SK&F 29661 (Figure 4). The binding site of AdoHcyfactor (AdoMet). So, if PNMT evolved from COMT, it
represents a variation of backward evolution in which is particularly striking in that one entire face of the cofac-
tor is surrounded by a constellation of five tyrosines andthe chemistry (methylation) is retained but the binding
mode of the common substrate is altered to yield a two phenylalanines (Figure 4). Although the aromatic-
rich nature of the cofactor binding site is unusual in thedifferent product of the catalyzed reaction.
The functional diversity and structural complexity of MT enzymes whose structures are known, the presence
of tyrosines at the active site confirms chemical modifi-GNMT suggests that it evolved relatively recently. Fur-
thermore, the strikingly comparable embellishments in cation studies from our laboratory showing that tyro-
sines are important for hPNMT function [18]. The seventhe MT folds of PNMT and GNMT provide compelling
evidence for a direct evolutionary relationship. The aromatic residues of the cofactor binding site are con-
served among the known PNMTs, but are not conservedstructures therefore support the following evolutionary
process: PNMT evolved from COMT, via a backward in other AdoMet MTs. Indeed, four of the tyrosines and
one phenylalanine are contributed from sequence inser-evolution event, and the PNMT fold was subsequently
recruited in the evolution of the structurally and function- tions in the common MT fold. Curiously, three of the five
tyrosines (Tyr35, Tyr40, and Tyr85) form hydrogen bondsally complex GNMT enzyme. PNMT therefore represents
an important link in the evolution of a highly regulated to the same functional group of the cofactor product,
the carboxylate. The large number of residues inter-and multifunctional tetrameric enzyme (GNMT) from a
simple monomeric enzyme (COMT). acting with the cofactor carboxylate is unusual for MTs.
For example, the carboxylate of AdoMet in COMT inter-This proposed evolutionary model has important con-
sequences. First, it supports the notion that the COMT acts only with a serine (Ser72, which aligns with Tyr85
of PNMT), and GNMT has no direct interactions with thefold represents an old and archetypal MT scaffold. Sec-
ond, it provides independent support for the concepts of cofactor carboxylate.
The amino group of AdoHcy interacts with hPNMTboth backward evolution and fold recruitment in protein
evolution. Third, if PNMT evolved from COMT, then the through hydrogen bonds to the main chain oxygens of
Gly79, Ser80, and Ala181. These specific interactionsproduct of the PNMT reaction, adrenaline, is a relative
newcomer in the catecholamine family. This implies that are generally not conserved in other MTs. For compari-
son, the amino group of AdoMet in COMT interacts withthe noradrenaline synthesis and inactivation pathway
may have been in place before the evolution of the syn- the main chain oxygen of Gly66 (which aligns with Gly79
in hPNMT) and with side chains of two residues (Ser72thetic step to produce adrenaline.
and Asp141). In GNMT, there are no direct interactions
to the amino group of the cofactor.Cofactor Binding Site
The crystal structure of the enzyme ternary complex The hydroxyls of the AdoHcy ribose ring form hydro-
gen bonds to hPNMT through the side chains of Asp101reveals the interactions formed between hPNMT and
Structure of Adrenaline-Synthesizing Enzyme PNMT
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Figure 3. Comparison of PNMT, COMT, and GNMT
(a) Structures of (left) hPNMT, (middle) rat COMT [12], and (right) rat GNMT [15] showing the equivalent core regions of the three polypeptide
folds in gray. For hPNMT, bound AdoHcy is shown in orange, SK&F 29661 is shown in yellow, and regions contributing to the active site
cover are shown in blue. The polyproline section of the structure is green, and the inserted helices 4 and 5 are pink. For COMT, bound
AdoMet is shown in orange, 3,5-dinitrocatechol is shown in yellow, Mg is shown in green, the N-terminal 40 residues are shown in blue, and
helix C is shown in green. For GNMT, bound AdoHcy is shown in orange (there is no inhibitor/substrate in the crystal structure of GNMT),
residues covering the active site are shown in blue, the short helical insert is shown in pink, and helix C is shown in green. The orientation
of hPNMT is similar to that in Figure 2, except that it is rotated 90 around the vertical axis.
(b) A topology diagram of hPNMT, COMT, and GNMT, using the same coloring scheme as in the upper panel. In addition, the approximate
positions of the residues that interact with ligands are shown as orange dots (for cofactor/cofactor product), yellow dots (for inhibitor), and
green dots (for Mg).
and Asn106 (data not shown). One of the ribose hydrox- one face of the ribose ring in all three enzymes, Tyr27
in PNMT, Trp143 in COMT, and His142 in GNMT, butyls (O3) also makes an unfavorable contact (2.9 A˚) with
the main chain C of Gly81. This glycine is conserved these residues are contributed from different regions of
sequence.among known PNMTs, but is not always found in other
AdoMet MTs. We predict that mutation of Gly81 would Chemical modification studies in PNMTs have impli-
cated a cysteine as being essential for catalysis [18],significantly reduce the binding affinity for the cofactor
in PNMT. The ribose hydroxyl interaction with an acidic and site-directed mutagenesis studies have identified
Cys183 as being important for the binding of AdoMetresidue is a highly conserved interaction in the MT fam-
ily. For example, the equivalent of Asp101 is Glu90 in [19, 20]. These observations are confirmed by the crystal
structure of hPNMT, which shows that Cys183 formsCOMT and Asp85 in GNMT. An aromatic residue covers
Table 2. Comparison of Three Small Molecule MT Structures
PNMT COMT GNMT
Number of residues 282 221 292
Quaternary structure monomer monomer dimer and tetramer
Structural comparison PNMT and COMT PNMT and GNMT COMT and GNMT
Number of residues superimposed 115 144 128
Number of identical residues 14 26 16
Sequence identity (%) 12.2 18.1 12.5
Rmsd (A˚) 2.3 2.1 2.2
Structure
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cofactor binding site, an unusually specific acceptor site
for the amino acid portion of the cofactor, and a novel
cysteine interaction with the adenine moiety.
Substrate/Inhibitor Binding Site
The PNMT inhibitor SK&F 29661 is a relatively simple
molecule, comprising a tetrahydroisoquinoline system
substituted with a sulfonamide at the 7 position (Figure
1). In the crystal structure of PNMT, the aromatic ring
of SK&F 29661 is sandwiched between the side chains
of Phe182 and Asn39, and the aliphatic ring is 3.7 A˚
from Val269 (data not shown). The aliphatic amine forms
a hydrogen bond to Glu219 (Figure 4) and water-medi-
ated hydrogen bonds to the side chains of Asp267 and
Asn39. The amine is also within 3.5 A˚ of the aromatic
ring of Tyr222, suggesting a possible amino-aromatic
interaction.
Both sulfonamide oxygens of SK&F 29661 interact
with the side chain of Lys57. One of the oxygens also
makes water-mediated interactions with the main chain
of Arg44 and the side chain of Tyr126. This same oxygen
makes an unfavorable interaction with the main chain
oxygen of Asn39 (data not shown). The sulfonamide
nitrogen forms no favorable interactions with the en-
zyme, in agreement with our predictions from earlier
structure-activity work [21]. However, this nitrogen is
within 3.5 A˚ of the guanidine group of Arg44 and the 
Figure 4. Inhibitor and Cofactor Binding in hPNMT methyl of Met258 (data not shown), suggesting that
Stereo images of the hPNMT binding sites. For clarity, not all resi- other substituents at this position might improve binding
dues that interact with the inhibitor and cofactor product are in- affinity.
cluded.
The experimentally determined binding mode of SK&F
(a) The binding mode of AdoHcy (orange), showing the five tyrosines
29661 allows us to model the substrate noradrenalineand two phenylalanines of hPNMT that surround one face of the
into the active site of hPNMT (Figure 4). Our modelcofactor product.
shows that many of the residues that interact with SK&F(b) The binding mode of SK&F 29661 (yellow) to hPNMT.
29661 can also interact with noradrenaline. For example,(c) The proposed binding mode of noradrenaline (green) to hPNMT,
the aromatic ring of noradrenaline stacks betweenalso showing the bound conformation of AdoHcy (orange).
Phe182 and Asn39, as in SK&F 29661. The catechol
hydroxyls of noradrenaline replace the sulfonamide of
SK&F 29661 and also form interactions with Lys57. How-part of the binding site for the adenine ring of AdoHcy.
Cys183 is conserved among PNMTs, but it is not con- ever, an additional interaction is formed between one
of the catechol hydroxyls and the side chain of Tyr40.served in other AdoMet MTs (the equivalent adenine
binding residue in COMT is His142, and, in GNMT, it is The water-mediated interactions observed between the
sulfonamide of SK&F 29661 and Arg44 and Tyr126 areTrp117). The adenine ring stacks between the side
chains of Cys183 and Phe102 in hPNMT (Figure 4) and not present in the noradrenaline model.
An important feature of the model is that the amineforms two hydrogen bonds, one between N1 and the
main chain nitrogen of Val159, and the second between of noradrenaline does not superimpose with the amine
of SK&F 29661. Rather, it is the -hydroxyl of noradrena-N6 and the side chain of Asp158. Residues that interact
with the adenine ring of COMT and GNMT are generally line that binds in the same region of space as the amine
of SK&F 29661. This is in agreement with our previouscontributed from the same region of sequence as in
hPNMT, but the side chain type is not conserved. For structure-activity relationship studies on phenylethanol-
amine substrates and benzylamine inhibitors that sug-example, the equivalent to Phe102 is Met91 in COMT
and Ala86 in GNMT. The equivalent of Asp158 is Gln120 gest that SK&F 29661 binds in an alternate mode to that
of noradrenaline [22] and to other inhibitors such asin COMT and Asn116 in GNMT.
In summary, the location of the binding site of the SK&F 64139 [23]. Significantly, our model places the
noradrenaline amine within the required distance (5.0 A˚)cofactor in hPNMT is the same as that in other MTs,
and, in many cases, residues that interact with the cofac- from the cofactor sulfur for methylation to occur. In con-
trast, the amine of SK&F 29661 in the crystal structuretor are contributed from the same part of the fold, based
on a structure-based sequence alignment. However, the is more than 7 A˚ from the AdoHcy sulfur.
The -hydroxyl of noradrenaline has been shown tochemistry (side chain identity) of the specific interac-
tions is generally not conserved between PNMT, COMT, be critical for orienting the amine for methylation by
AdoMet [24]. Thus, phenylethylamine, which lacks theand GNMT, except in a few specific cases. In particular,
PNMT is unique in having a tyrosine/phenylalanine-rich -hydroxyl, is not a substrate for PNMT. Only by making
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rigid analogs of noradrenaline is it possible to produce design of inhibitors with improved profiles will be achiev-
able. Improved inhibitors will enable the precise charac-PNMT substrates that do not have a -hydroxyl group
[25]. The proposed interactions between the -hydroxyl terization of the CNS role of adrenaline and could even-
tually be useful in the development of novel therapeuticof noradrenaline and Glu219 and Asp267 may therefore
be critical for PNMT substrate binding and selectivity. agents.
An unexpected finding from this work was that PNMTThe amine of the modeled noradrenaline substrate is
within hydrogen bonding distance of Glu219 and is represents a direct link in the proposed evolution of a
highly complex enzyme from a simple fold. The evidencewithin amino-aromatic stacking distance of Tyr222. Both
of these residues may therefore be important for cataly- is the remarkable structural similarity between PNMT
and another enzyme, GNMT, despite low sequencesis in that they may help to activate or stabilize the
amine for methylation. identity. All AdoMet-dependent methyltransferases are
likely to have an underlying fold similarity, but these two
enzymes also share a strikingly similar embellishmentImplications for Inhibitor Design
pattern. No other known methyltransferase structureOur ultimate goal in determining the structure of PNMT
shares the same pattern or has a covered active site likeis to use it in the design of better, more potent and
that of PNMT/GNMT. The structural analysis of PNMTselective PNMT inhibitors. The structure of hPNMT re-
provides unanticipated and independent evidence forported here, showing the binding mode of a known inhib-
both backward evolution and fold recruitment events initor and comparing hPNMT with COMT, shows that there
protein evolution.is scope to do this. First, the covered active site com-
prises several unique structural features contributed Experimental Procedures
from different regions of the PNMT polypeptide. This
indicates that selectivity can be designed into PNMT Protein Expression and Crystallization
Human PNMT was cloned, overexpressed, and purified as describedinhibitors by forming additional interactions with these
previously [18]. A detailed description of the crystallization condi-distinct regions. Second, the crystal structure shows
tions will be published elsewhere. Briefly, crystals of hPNMT inthat SK&F 29661, one of the most potent PNMT inhibi-
complex with AdoHcy and SK&F 29661 were grown by hanging-
tors available, does not utilize all of the binding capacity drop vapor diffusion from PEG 6K and lithium chloride. Crystals
in the PNMT active site. This suggests that additional (space group P43212 and unit cell dimensions a  b  94.3 A˚, c 
functional groups on the tetrahydroisoquinoline moiety 187.7 A˚) appeared after several weeks. Crystals were cryoprotected
with 20%–25% glycerol and flash frozen in a gaseous nitrogenor novel scaffolds could be designed to utilize the extra
stream at 100K for data measurement. The asymmetric unit con-binding capacity to increase inhibitor potency. Third, it
tained two molecules of hPNMT, each complexed with inhibitormay be possible to displace bound waters that mediate
SK&F 29661 and cofactor product AdoHcy.
hydrogen bonds between SK&F 29661 and hPNMT to
improve the binding energy of a designed inhibitor com- Data Measurement and Structure Determination
pared with that of SK&F 29661 by increasing entropy. X-ray diffraction data were measured using a Rigaku RU200 copper
rotating anode generator operating at 46 kV, 60 mA and an RAXIS–Such inhibitors will be an important addition to the ar-
IIC image plate area detector. Monochromatic X-rays were pro-mory of pharmacological tools for studying catechola-
duced using a Yale mirror system, and an Oxford Cryostream wasmines in the CNS and could eventually prove useful
used for cryocrystallographic data measurement. A mercury deriva-as lead compounds in the development of therapeutic
tive was obtained by soaking a PNMT crystal in 2 mM ethylmercury-
agents with novel pharmacological activity. phosphate (EMP) for 10 min. A second derivative was obtained
by cocrystallizing hPNMT with an iodinated inhibitor [23] (7-iodo-
1,2,3,4-tetrahydroisoquinoline) in place of SK&F 29661. Crystallo-Biological Implications
graphic data were processed using DENZO and SCALEPACK [26].
Two mercury sites were found using SHELXL-97 [27]. The other four
PNMT catalyzes the synthesis of adrenaline. It achieves mercury sites and two iodine sites were found by difference Fourier
peak analysis using PHASES [28]. Heavy atom refinement and phas-this by binding noradrenaline and a methylating cofac-
ing were performed with SHARP [29], followed by solvent flippingtor, AdoMet, and bringing them together in such a way
and flattening with SOLOMON [30]. This gave an excellent electronthat AdoMet specifically transfers its methyl group to the
density map phased at 3.0 A˚. Model building was performed withamine of noradrenaline, thereby generating adrenaline.
O [31], and the structure was refined by the maximum likelihood
Adrenaline is produced in significant amounts in specific method against native data to 2.4 A˚ using CNS [32]. Noncrystallo-
regions of the CNS; its role in the CNS is not clear; graphic symmetry restraints were used in the early stages of refine-
ment but were removed at the later stages. Individual B factor refine-although, it has been implicated in critical processes
ment and the inclusion of bound waters was performed at the finalsuch as the control of blood pressure and respiration.
stages of refinement.Since PNMT catalyzes the final step in adrenaline syn-
The final model consists of two molecules of hPNMT (numberedthesis, it represents a prime target for pharmacological
22–282 and 514–780), each bound with AdoHcy and SK&F 29661,
intervention to characterize the role of CNS adrenaline. plus 126 waters. No electron density was observed for residues 1–21
The problem is that currently available PNMT inhibitors from molecule 1 and residues 501–513 and 781–782 from molecule 2,
and these were not included in the final model. The rmsd for theare not practical for such studies because none com-
comparison of the two molecules in the asymmetric unit is 0.49 A˚bines the three critical properties of potency, selectivity,
for 259 C atoms (residues 22–280). This reduces to 0.32 A˚ for 248and CNS activity. The crystal structure of human PNMT
C atoms when residues from the N terminus, the polyproline region,reported here reveals the details of the binding interac-
and from a loop connecting B and 4 are removed from the com-
tions between enzyme, inhibitor/substrate, and cofac- parison. Cis-prolines are modeled at residue Pro43 in both mole-
tor, showing that there is unused binding potential in cules of the asymmetric unit (43 and 543) and at Pro174 (174 and
674). The average B value calculated from all atoms in the structurethe active site. This suggests that the structure-based
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is 47 A˚2, which compares well with the Wilson B factor of 44 A˚2 8. Black, J., Waeber, B., Bresnahan, M.R., Gavras, I., and Gavras,
H. (1981). Blood pressure response to central and/or peripheralcalculated from diffraction data using TRUNCATE [33]. The average
B values for protein (47 A˚2), inhibitor (46 A˚2), AdoHcy (50 A˚2), and inhibition of phenylethanolamine N-methyltransferase in normo-
tensive and hypertensive rats. Circ. Res. 49, 518–524.water (46 A˚2) are all similar. The relatively low average B value for
waters reflects the stringent criteria used for including waters in this 9. Toomey, R.E., Horng, J.S., Hemrick-Luecke, S.K., and Fuller,
R.W. (1981). 2-adrenoceptor affinity of some inhibitors of nor-structure (electron density peak at 1 in 3Fo-2Fc maps and at 3 in
Fo-Fc maps, and an Rfree drop after inclusion of waters). As a result, epinephrine N-methyltransferase. Life Sci. 29, 2467–2472.
10. Leszczynski, J.F., and Rose, G.D. (1986). Loops in globular pro-there are relatively few waters included in the structure (on average,
one water for every four protein residues), and these are well ordered teins: a novel category of secondary structure. Science 234,
849–855.and therefore have B factors similar to those of protein atoms.
Although dithiothreitol (DTT) was added to the crystallization con- 11. Wilmot, C.M., and Thornton, J.M. (1988). Analysis and prediction
of the different -turns in proteins. J. Mol. Biol. 203, 221–232.ditions, symmetry-related intermolecular disulfide bonds (between
Cys48–Cys639 and Cys139–Cys548) are present in the crystal struc- 12. Vidgren, J., Svensson, L.A., and Liljas, A. (1994). Crystal struc-
ture of catechol O-methyltransferase. Nature 368, 354–358.ture. Since PNMT crystals do not appear until several weeks after
13. Fu, Z.,et al., and Takusagawa, F. (1996). Crystal structure ofsetup, it is likely that DTT inhibits crystallization. However, the disul-
glycine N-methyltransferase from rat liver. Biochemistry 35,fides are not required for PNMT activity (M.J.M. and J.M.C., unpub-
11985–11993.lished data), and the active form of PNMT is monomeric, based on
14. Bhat, R., and Bresnick, E. (1997). Glycine N-methyltransferaselight scattering experiments (J.L.M., unpublished data) and size-
is an example of functional diversity. J. Biol. Chem. 272, 21221–exclusion chromatography (M.J.M. and J.M.C., unpublished data).
21226.
15. Huang, Y., et al., and Takusagawa, F. (2000). Mechanisms forStructural Analysis
auto-inhibition and forced product release in glycine N-methyl-The crystal structures of methyltransferases were visualized, super-
transferase: crystal structures of wild-type, mutant R175K andimposed, and compared using O [31]. Figures were generated using
S-adenosylhomocysteine-bound R175K enzymes. J. Mol. Biol.Molscript [34], Raster3D [35], Setor [36], and O [31].
298, 149–162.
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Accession Numbers
The three-dimensional coordinates of the hPNMT structure and the
structure factor file have been deposited with the Protein Data Bank
[37] with accession code 1HNN.
